Allied Market Research
Loading...
0
New
New
2021
Anti-inflammatory Therapeutics Market

Anti-Inflammatory Therapeutics Market by Drug Class (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, and Biologics), Indication Type (Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Anti-inflammatory Bowel Disease (IBD), and Other Anti-inflammatory Diseases): Global Opportunity Analysis and Industry Forecast, 2021–2028

A00196
Pages: 190
Jun 2021 | 30746 Views
   
Author(s) : Sushant Terdale , Onkar Sumant
Tables: 91
Charts: 47
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Anti-inflammatory Therapeutics Market

Request Now !

The global anti-inflammatory therapeutics market size was $98,026 million in 2020 and is projected to reach $125,552 million by 2028, registering a CAGR of 4.0% from 2021 to 2028

Anti-inflammatory therapeutic is a drug that eases acute & chronic pain as well as inflammation (redness, swelling, and pain). Anti-inflammatory agents block certain substances in the body that cause inflammation. They are used to treat many different conditions such as treat migraines, headaches, rheumatic arthritis, sprains, and menstrual pain. Furthermore, some anti-inflammatory agents such as celecoxib and ibuprofen are being studied for the prevention and treatment of cancer. In addition, they can provide faster relief as compared to other drugs. They are capable of lowering the levels of prostaglandins and the chemicals responsible for inflammation, thereby reducing pain and swelling. Anti-inflammatory drugs usually target the anti-inflammatory mediators or enzymes. These drugs are often used in combination of other drugs. Inflammation is the most prevalent treatable symptom among many immune and respiratory diseases. They are available in the form of tablets, capsules, suppositories (capsules inserted into the bottom), creams, gels, and injections. The major types of anti-inflammatory drugs include ibuprofen, naproxen, diclofenac, celecoxib, mefenamic acid, etoricoxib, and indomethacin 

Anti-Inflammatory-Therapeutics-Market-2020-2028

Get more information on this report : Request Sample Pages

The growth of the global anti-inflammatory market has been driven by factors such as increase in prevalence of autoimmune & respiratory conditions, new drugs in pipeline, and surge in adoption of anti-inflammatory drugs. Furthermore, the demand for anti-inflammatory drugs has been increasing exponentially, owing to the emergence of anti-inflammatory biologics that are more targeted, effective, and with lesser side effects as compared to conventional drugs. Moreover, rise in awareness of anti-inflammatory therapeutics and attractive government initiatives toward the treatment of inflammation with nonsteroidal anti-inflammatory drugs in Asia-Pacific and LAMEA are expected to drive the market growth during the analysis period. However, factors such as side effects of anti-inflammatory drugs and patent expiry issues of blockbuster drugs (such as Remicade) impede the market growth. 

The impact of COVID-19 pandemic is expected to remain positive for the anti-inflammatory therapeutics market, owing to the inflammation caused by SARS-COV 2. SARS-CoV-2 is a beta coronavirus causing severe anti-inflammatory pneumonia, as COVID-19 can cause severe inflammation to patients diagnosed with it. According to reports, cytokine storm is strongly responsible for death in such patients. Some of the consequences of severe inflammation and cytokine storms include acute respiratory distress syndrome, acute lung injury, and multiple organ dysfunction syndromes, which lead to increase in the research and the development of anti-inflammatory drugs for the treatment of inflammation caused by COVID-19. For example, many clinical trials are currently underway to alleviate this destructive inflammation. One of them is NLRP3 inflammasome, which targets multiple mechanisms associated with COVID-19 excessive inflammation. Thus, such factors have positively impacted the market growth during the global health crisis. 

Global Anti-inflammatory Therapeutics Market Segmentation  

The global anti-inflammatory therapeutics market is segmented into indication, drug class, and region. Depending on indication, the market is categorized into arthritis, respiratory diseases, multiple sclerosis, psoriasis, anti-inflammatory bowel disease (IBD), and other anti-inflammatory diseases. By drug class, it is segregated into nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

Drugs class segment review

Depending on drugs class, the anti-inflammatory biologics segment held the largest share in 2020, and is anticipated to maintain its dominance during the forecast period, owing to increase in patient population suffering from chronic disease and unavailability of effective treatments. Moreover, increase in healthcare spending along with rise in awareness of biologics, especially, in emerging markets represent a huge market potential for biologics.

Anti-Inflammatory Therapeutics Market
By Drug class

Your browser does not support the canvas element.

Anti-inflammatory Biologics segment holds a dominant position in 2020

Get more information on this report : Request Sample Pages

Indication type segment review

By indication, the arthritis segment was the highest contributor to the anti-inflammatory therapeutics market. This is attributed to increase in prevalence of osteoarthritis and rheumatoid arthritis. In addition, rise in usage of topical drugs for treating arthritis pain and surge in geriatric population across the globe fuel the growth of the market.

Anti-Inflammatory Therapeutics Market
By Indication

Your browser does not support the canvas element.

Arthritis segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Region segment review

Region wise, North America garnered the largest share in 2020, and is anticipated to maintain its dominance from 2020 to 2028, due to high expenditure on R&D, presence of major players & their product availability, and well-established healthcare infrastructure in the region. However, Asia-Pacific is expected to register the highest CAGR during the forecast period, as governments of Asian countries are investing in the development of healthcare infrastructure. Moreover, rise in usage of OTC NSAIDs and increase in geriatric population are expected to contribute toward the anti-inflammatory therapeutics market growth.

Anti-Inflammatory Therapeutics Market
By Region

2028
North America 
Europe
Asia-pacific
Lamea

Asia Pacific region would exhibit the highest CAGR of 5.2% during 2021-2028.

Get more information on this report : Request Sample Pages

The key market players profiled in the report include Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis, F. Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC, and Amgen.

Key Benefits For Stakeholders

  • This report entails a detailed quantitative analysis along with the current global anti-inflammatory therapeutics market trends from 2020 to 2028 to identify the prevailing opportunities along with the strategic assessment.
  • The anti-inflammatory therapeutic market forecast is studied from 2021 to 2028.
  • The anti-inflammatory therapeutics market size and estimations are based on a comprehensive analysis of key developments in the ultrasound device industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the anti-inflammatory therapeutics market.

Key Market Segments

By Drug Class

  • Nonsteroidal Anti-inflammatory Diseases (NSAIDs)
  • Corticosteroids
  • Biologics

By Indication Type

  • Arthritis
  • Respiratory Disease
  • Multiple Sclerosis
  • Psoriasis
  • Anti-inflammatory Bowel Disease (IBD)
  • Other Anti-inflammatory disease

By Region 

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil 
    • South Africa
    • Saudi Arabia 
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key Findings

3.2.1.Top Investment Pockets
3.2.2.Key forces shaping the anti-inflammatory therapeutics market

3.3.Market dynamics

3.3.1.Drivers

3.3.1.1.Rising incidences of autoimmune and respiratory conditions
3.3.1.2.New drug pipelines
3.3.1.3.Increasing adoption rate of anti -Inflammatory drugs

3.3.2.Restraint

3.3.2.1.side effects of anti -Inflammatory drugs
3.3.2.2.Patent expires

3.3.3.Opportunity

3.3.3.1.Developing biosimilars for the existing drugs

3.4.Market dynamics

CHAPTER 4:GLOBAL ANTI -INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.Anti- Inflammatory Biologics

4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country

4.3.Nonsteroidal Anti- -Inflammatory Drugs (NSAIDs)

4.3.1.Key trends and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Corticosteroids

4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

CHAPTER 5:GLOBAL ANTI-INFLAMMATORY HERAPEUTICS MARKET BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Arthritis.

5.2.1.Market size and forecast
5.2.2.Market analysis, by country

5.3.Psoriasis

5.3.1.Market size and forecast
5.3.2.Market analysis, by country

5.4.Respiratory Diseases

5.4.1.Market size and forecast
5.4.2.Market analysis, by country

5.5.Multiple sclerosis

5.5.1.Market size and forecast
5.5.2.Market analysis, by country

5.6.Anti-Inflammatory Bowel Disease (IBD)

5.6.1.Market size and forecast
5.6.2.Market analysis, by country

5.7.Other Anti-Inflammatory disease

5.7.1.Market size and forecast
5.7.2.Market analysis, by country

CHAPTER 6:ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key trends and opportunities
6.2.2.Market size and forecast, by country
6.2.3.Market size and forecast, by drug class
6.2.4.Market size and forecast, by Indication
6.2.5.U.S.

6.2.5.1.U.S. market size and forecast, by drug class
6.2.5.2.U.S. market size and forecast, by Indication

6.2.6.Canada

6.2.6.1.Canada market size and forecast, by drug class
6.2.6.2.Canada market size and forecast, by Indication

6.2.7.Mexico

6.2.7.1.Mexico market size and forecast, by drug class
6.2.7.2.Mexico market size and forecast, by Indication

6.3.Europe

6.3.1.Key trends and opportunities
6.3.2.Europe market size and forecast, by country
6.3.3.Europe market size and forecast, by drug class
6.3.4.Europe market size and forecast, by Indication

6.3.5.Germany

6.3.5.1.Germany market size and forecast, by drug class
6.3.5.2.Germany market size and forecast, by Indication

6.3.6.UK

6.3.6.1.UK market size and forecast, by drug class
6.3.6.2.UK market size and forecast, by Indication

6.3.7.Spain

6.3.7.1.Spain market size and forecast, by drug class
6.3.7.2.Spain market size and forecast, by Indication

6.3.8.France

6.3.8.1.France market size and forecast, by drug class
6.3.8.2.France market size and forecast, by Indication

6.3.9.Italy

6.3.9.1.Italy market size and forecast, by drug class
6.3.9.2.Italy market size and forecast, by Indication

6.3.10.Rest of Europe

6.3.10.1.Rest of Europe market size and forecast, by drug class
6.3.10.2.Rest of Europe market size and forecast, by Indication

6.4.Asia-Pacific

6.4.1.Key trends and opportunities
6.4.2.Asia-Pacific market size and forecast, by country
6.4.3.Asia-Pacific market size and forecast, by drug class
6.4.4.Asia-Pacific market size and forecast, by Indication
6.4.5.Japan

6.4.5.1.Japan market size and forecast, by drug class
6.4.5.2.Japan market size and forecast, by Indication

6.4.6.China

6.4.6.1.China market size and forecast, by drug class
6.4.6.2.China market size and forecast, by Indication

6.4.7.India

6.4.7.1.India market size and forecast, by drug class
6.4.7.2.India market size and forecast, by Indication

6.4.8.Australia

6.4.8.1.Australia market size and forecast, by drug class
6.4.8.2.Australia market size and forecast, by Indication

6.4.9.South Korea

6.4.9.1.South Korea market size and forecast, by drug class
6.4.9.2.South Korea market size and forecast, by Indication

6.4.10.Rest of Asia-Pacific

6.4.10.1.Rest of Asia-Pacific market size and forecast, by drug class
6.4.10.2.Rest of Asia-Pacific market size and forecast, by Indication

6.5.LAMEA

6.5.1.Key market trends and opportunities
6.5.2.LAMEA market size and forecast, by country
6.5.3.LAMEA market size and forecast, by drug class
6.5.4.LAMEA market size and forecast, by Indication
6.5.5.Brazil

6.5.5.1.Brazil market size and forecast, by drug class
6.5.5.2.Brazil market size and forecast, by Indication

6.5.6.South Africa

6.5.6.1.South Africa market size and forecast, by drug class
6.5.6.2.South Africa market size and forecast, by Indication

6.5.7.Saudi Arabia

6.5.7.1.Saudi Arabia market size and forecast, by drug class
6.5.7.2.Saudi Arabia market size and forecast, by Indication

6.5.8.Rest of LAMEA

6.5.8.1.Rest of LAMEA market size and forecast, by drug class
6.5.8.2.Rest of LAMEA market size and forecast, by Indication

CHAPTER 7:COMPANY PROFILES

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments

7.2.Amgen Inc

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product Portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments

7.3.AstraZeneca PLC.

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product Portfolio
7.3.5.Business performance

7.4.Eli Lily and Company.

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance

7.5.F. Hoffmann-La Roche AG

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments

7.6.GlaxoSmithKline plc

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance

7.7.Johnson & Johnson

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance

7.8.Merck & Co., Inc.

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance

7.9.Novartis AG

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance

7.10.PFIZER INC.

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 02.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ANTI-INFLAMMATORY BIOLOGICS, BY REGION, 2020–2028 ($MILLION)
TABLE 03.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR NONSTEROIDAL ANTI -INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2020–2028 ($MILLION)
TABLE 04.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR CORTICOSTEROIDS, BY REGION, 2020–2028 ($MILLION)
TABLE 05.ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 06.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ARTHRITIS, BY REGION, 2020–2028 ($MILLION)
TABLE 07.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR PSORIASIS, BY REGION, 2020–2028 ($MILLION)
TABLE 08.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR RESPIRATORRY DISEASE, BY REGION, 2020–2028 ($MILLION)
TABLE 09.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR MULTIPLE SCLEROSIS, BY REGION,  2020–2028 ($MILLION)
TABLE 10.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR IANTI-INFLAMMATORY BOWEL DISEASE (IBD), BY REGION, 2020–2028 ($MILLION)
TABLE 11.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR OTHER IANTI-INFLAMMATORY DISEASE, BY REGION, 2020–2028 ($MILLION)
TABLE 12.ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY REGION, 2020–2028 ($MILLION)
TABLE 13.NORTH AMERICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 14.NORTH AMERICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028($MILLION)
TABLE 15.NORTH AMERICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 16.U.S. ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 17.U.S. ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 18.CANADA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 19.CANADA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 20.MEXICO ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028($MILLION)
TABLE 21.MEXICO ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 22.EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 23.EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 24.EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 25.GERMANY ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 26.GERMANY ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 27.UK ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 28.UK ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 29.SPAIN ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 30.SPAIN ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 31.FRANCE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 32.FRANCE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 33.ITALY ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 34.ITALY ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 35.REST OF EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 36.REST OF EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028($MILLION)
TABLE 37.ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY COUNTRY, 2020–2026 ($MILLION)
TABLE 38.ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 39.ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 40.JAPAN ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 41.JAPAN ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 42.CHINA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 43.CHINA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 44.INDIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 45.INDIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 46.AUSTRALIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 47.AUSTRALIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 48.SOUTH KOREA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 49.SOUTH KOREA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 50.REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 51.REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 52.LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 53.LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 54.LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 55.BRAZIL ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 56.BRAZIL ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 57.SOUTH AFRICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 58.SOUTH AFRICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 59.SAUDI ARABIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 60.SAUDI ARABIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 61.REST OF LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020–2028 ($MILLION)
TABLE 62.REST OF LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020–2028 ($MILLION)
TABLE 63.ABBVIE: COMPANY SNAPSHOT
TABLE 64.ABBVIE: OPERATING SEGMENTS
TABLE 65.ABBVIE: PRODUCT PORTFOLIO
TABLE 66.AMGEN: COMPANY SNAPSHOT
TABLE 67.AMGEN: OPERATING SEGMENTS
TABLE 68.AMGEN: PRODUCT PORTFOLIO
TABLE 69.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 70.ASTRAZENECA: BUSINESS SEGMENT
TABLE 71.ELI LILLY: COMPANY SNAPSHOT
TABLE 72.ELI LILLY: OPERATING SEGMENTS
TABLE 73.ELI LILLY: PRODUCT PORTFOLIO
TABLE 74.ROCHE: COMPANY SNAPSHOT
TABLE 75.ROCHE: OPERATING SEGMENTS
TABLE 76.ROCHE: PRODUCT PORTFOLIO
TABLE 77.GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 78.GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 79.GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 80.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 81.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 82.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 83.MERCK: COMPANY SNAPSHOT
TABLE 84.MERCK: OPERATING SEGMENTS
TABLE 85.MERCK: PRODUCT PORTFOLIO
TABLE 86.NOVARTIS: COMPANY SNAPSHOT
TABLE 87.NOVARTIS: OPERATING SEGMENTS
TABLE 88.NOVARTIS: PRODUCT PORTFOLIO
TABLE 89.PFIZER: COMPANY SNAPSHOT
TABLE 90.PFIZER: OPERATING SEGMENTS
TABLE 91.PFIZER: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.ANTI-INFLAMMATORY THERAPEUTIC MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF BUYERS
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05.MODERATE THREAT OF SUBSTITUTION
FIGURE 06.MODERATE THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE COMPETITVE RIVARLY
FIGURE 08.ANTI-INFLAMMATORY THERAPEUTIC MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 09.COMPARATIVE SHARE ANALYSIS OF ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ANTI- -INFLAMMATORY BIOLOGICS, BY COUNTRY, 2020 & 2028(%)
FIGURE 10.COMPARATIVE SHARE ANALYSIS OF ENTERAL ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR NONSTEROIDAL ANTI -INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2020 & 2028 (%)64
FIGURE 11.COMPARATIVE SHARE ANALYSIS OF ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2020 & 2028 (%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF CANCER ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ARTHRITIS, BY COUNTRY, 2020 & 2028 (%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CANCER ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ARTHRITIS, BY COUNTRY, 2020 & 2028 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR RESPIRATORY DISEASE, BY COUNTRY, 2020 & 2028 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR MULTIPLE SCLEROSIS BY COUNTRY, 2020 & 2028 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ANTI-INFLAMMATORY BOWEL DISEASE (IBD) BY COUNTRY, 2020 & 2028 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR OTHER ANTI-INFLAMMATORY DISEASE BY COUNTRY, 2020 & 2028 (%)
FIGURE 18.ABBVIE: NET SALES, 2018–2020 ($MILLION)
FIGURE 19.ABBVIE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20.ABBVIE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 21.NET SALES, 2018–2020 ($MILLION)
FIGURE 22.AMGEN: NET SALES BY DIVISION, 2020 (%)
FIGURE 23.AMGEN: NET SALES BY REGION, 2020 (%)
FIGURE 24.NET SALES, 2018–2020 ($MILLION)
FIGURE 25.ASTRAZENECA REVENUE SHARE BY BUSINESS UNIT, 2020 (%)
FIGURE 26.ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 27.NET SALES, 2018–2020 ($MILLION)
FIGURE 28.ELI LILLY REVENUE SHARE BY BUSINESS UNIT, 2020 (%)
FIGURE 29.ELI LILLY: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 30.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32.ROCHE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 33.GLAXOSMITHKLINE: NET SALES, 2018–2020 ($MILLION)
FIGURE 34.GLAXOSMITHKLINE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 35.GLAXOSMITHKLINE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 36.NET SALES, 2018–2020 ($MILLION)
FIGURE 37.JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 38.JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 39.NET SALES, 2018–2020 ($MILLION)
FIGURE 40.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 41.MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 43.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 45.PFIZER NET SALES, 2019–2020 ($MILLION)
FIGURE 46.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 47.PFIZER: REVENUE SHARE BY GEOGRAPHY, 2018 (%)

 
 

The global anti-inflammatory therapeutic market is expected to witness a steady growth in the future. The market has drawn the interest of the healthcare industry, owing to increase in chronic & lifestyle-related diseases, rise in geriatric population, and increase in prevalence of chronic diseases. In addition, rise in R&D investments made by the government in the healthcare sector propels the growth of the market. However, lack of awareness, patent expires, side effects, and stringent regulations for anti-inflammatory drugs usage projected to hinder the market growth. On the contrary, rise in an adoption of anti-inflammatory drugs and developing biosimilar drugs are expected to offer remunerative opportunities for the expansion of the anti-inflammatory therapeutic market. In addition, increase in product approval is expected to boost the market growth in the near future.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Anti-Inflammatory Therapeutics Market is $ 98,026.39 million in 2020

A. The forecast period in the report is from 2021 to 2028

A. The market value of Anti-Inflammatory Therapeutics Market in 2020 was Million

A. The base year for the report is 2020

A. Yes, Anti-Inflammatory Therapeutics Market companies are profiled in the report

A. The top companies that hold the market share in Anti-Inflammatory Therapeutics Market are are Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis

A. No, there is no value chain analysis provided in the Anti-Inflammatory Therapeutics Market report

A. The key trends in the Anti-Inflammatory Therapeutics Market are increasing autoimmune and respiratory conditions, new drugs in pipeline and increasing adoption of anti-inflammatory drugs

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Anti-inflammatory Therapeutics Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers